Advertisement

FDA Halves Initial Dose for Lunesta — Physician’s First Watch

Medical News |
May 16, 2014

FDA Halves Initial Dose for Lunesta

By Kelly Young

The FDA has recommended that the starting dose of the sleep drug eszopiclone (Lunesta) be lowered from 2 mg to 1 mg after a study found that patients taking higher doses were at increased risk for severe psychomotor and memory impairment the next morning.

The agency noted that the dose can be increased to 2 mg or 3 mg as needed, but it cautions people who take 3 mg against driving or doing other activities that require their full attention the next day.

A study of roughly 90 adults found that 3 mg of eszopiclone was linked to severe psychomotor and memory impairment 7.5 hours after taking the drug. Problems with driving, memory, and coordination can occur more than 11 hours after taking the evening dose.

The FDA is evaluating all sleep aid drugs for the potential to affect next-day mental alertness. It already required lowering Ambien doses over similar concerns.

Reader Comments (1)

Marilyn Edmundson Other, Retired

I have taken 3 mg of Lunesta for a year. A wonderful sleep aid with no psychomotor or memory impairment.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement